Spotlight Asset Group’s Relmada Therapeutics RLMD Stock Holding History

Spotlight Asset Group’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$60K	Hold	20,000	–	–	0.04%	129
2024 Q1	$93K	Hold	20,000	–	–	0.07%	113
2023 Q4	$60K	Hold	20,000	–	–	0.05%	126
2023 Q3	$60K	Hold	20,000	–	–	0.05%	126
2023 Q2	$49.2K	Hold	20,000	–	–	0.04%	138
2023 Q1	$140K	Buy	+20,000	New	+$69K	0.14%	72
2022 Q3	$140K	Buy	+20,000	New	+$554K	0.14%	72
2021 Q3	$793K	Hold	30,265	–	–	0.4%	51
2021 Q2	$969K	Buy	30,265 +5,700	+23%	+$198K	0.37%	53
2021 Q1	$865K	Buy	24,565 +1,856	+8%	+$64.9K	0.33%	60
2020 Q4	$728K	Buy	+22,709	New	+$780K	0.27%	58

Other funds holding RLMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Spotlight Asset Group's RLMD Position: Q2 2024 in Review

Spotlight Asset Group held its Relmada Therapeutics (RLMD) position steady in Q2 2024 at 20,000 shares worth $60K. The position accounts for 0.04% of the portfolio, ranked #129.

Spotlight Asset Group first reported a position in RLMD in Q4 2020 and has held it in 11 quarters since. The position peaked at $969K in Q2 2021. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

Spotlight Asset Group held 20,000 shares of Relmada Therapeutics worth $60K as of Q2 2024.
Spotlight Asset Group left its Relmada Therapeutics share count unchanged in Q2 2024.
Relmada Therapeutics made up 0.04% of Spotlight Asset Group's portfolio in Q2 2024, its #129 holding.
Spotlight Asset Group first reported a position in Relmada Therapeutics in Q4 2020 and has held it in 11 quarters since.
Spotlight Asset Group's Relmada Therapeutics position peaked at $969K in Q2 2021.
79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Spotlight Asset Group's 13F filing for Q2 2024, filed 24 Jul 2024.